Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Should You Buy the Dip on This Top Growth Stock?
Regeneron Pharmaceuticals faces headwinds with Eylea, its key eye disease treatment, due to biosimilar competition and a recent court decision favoring Amgen. Despite this, Regeneron's higher-dose Eylea and growth driver Dupixent, an eczema treatment, suggest resilience. Long-term biotech investors are advised to consider buying Regeneron shares on the dip.
9 Months of Treatment With Tralokinumab Results in Improved QoL, Itch, and Sleep
Nine months of tralokinumab treatment improved itch, sleep quality, and overall quality of life in adult atopic dermatitis patients, according to interim TRACE study results presented at the 2024 EADV Congress.
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
FDA approves Sanofi/Regeneron’s Dupixent for COPD, Eli Lilly invests $4.5B in new Indiana facility, AbbVie seeks FDA approval for lung cancer candidate Teliso-V, and AstraZeneca receives priority review for cancer drugs.
Chronic Urticaria Competitive Landscape Assessment 2024
The 'Chronic Urticaria: Competitive Landscape' report by ResearchAndMarkets.com details the current and future therapeutic market, highlighting key players like Regeneron/Sanofi (Dupixent) and Genentech/Novartis (Xolair). With over 60 million diagnosed cases in 16 countries, the report covers 42 pipeline molecules, including 3 in Phase III and 17 in Phase II. The US leads in trial sites for chronic urticaria, followed by China. The report also analyzes acquisition deals and provides strategic insights for market players.
Global LAG 3 Antibody FDA Approval Clinical Trials
Global LAG-3 Inhibitors Market expected to exceed USD 3 billion by 2029; Opdualag, first LAG-3 therapy, approved for melanoma. LAG-3 inhibitors show potential in combination therapies for various cancers and diseases. Key players include Bristol Myers Squibb, Roche, and Regeneron. Market valued at USD 625 million in 2023, projected to grow significantly.
Global LAG 3 Antibody FDA Approval Clinical Trials LAG 3 Inhibitors Market Future Growth
Global LAG-3 inhibitors market to exceed USD 3 billion by 2029, driven by the approval of Opdualag, the first LAG-3 therapy, and ongoing clinical trials evaluating LAG-3 inhibitors in combination therapies. Key players include Bristol Myers Squibb, Symphogen A/S, and Hoffmann-La Roche.
Eye on Pharma: High Strength Trastuzumab Biosimilar; Originator Coverage Removals
FDA approves 420 mg strength of Hercessi (trastuzumab-strf) biosimilar; UnitedHealth to remove Humira from preferred drug lists in favor of biosimilars; Evernorth offers interchangeable ustekinumab biosimilar at no cost; Samsung Bioepis receives positive opinion for aflibercept biosimilar.
As 2seventy Nears Breakeven, CEO Chip Baird Explains How the Team Survived
Despite numerous challenges, 2seventy bio, formerly part of bluebird bio, remains focused on achieving profitability with its CAR T therapy Abecma. The company has undergone layoffs, pipeline reorganizations, and faced competition and FDA safety warnings. CEO Chip Baird predicts profitability next year, with potential growth strategies including acquisitions or licensing deals. The company's culture and resilience among its employees have been key to its survival.
FDA approves first-ever biologic for COPD
FDA approves dupilumab (Dupixent) as first biologic treatment for COPD in adults, showing 30-34% reduction in moderate or severe exacerbations in phase 3 trials BOREAS and NOTUS. Dupilumab, an IL-4 and IL-13 pathway inhibitor, is indicated for inadequately controlled COPD with eosinophilic phenotype.
Dupixent Gets FDA Approval for COPD
FDA approves Dupixent for COPD, offering a new biologic treatment option for 300,000 U.S. adults with inadequately controlled COPD and eosinophilic COPD. Dupixent, a monoclonal antibody, reduces flare-ups, improves lung function, and enhances quality of life. Common side effects include injection-site reactions and viral infections.
© Copyright 2025. All Rights Reserved by MedPath